181 – 190 of 192
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2006
-
Mark
High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients.
(
- Contribution to journal › Article
- 2005
-
Mark
Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.
(
- Contribution to journal › Article
-
Mark
ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis
(
- Contribution to journal › Article
-
Mark
Cyclin I is expressed in human breast cancer and closely associated with VEGF and KDR expression.
(
- Contribution to journal › Article
-
Mark
Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification.
(
- Contribution to journal › Article
-
Mark
Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response.
(
- Contribution to journal › Article
-
Mark
Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial.
(
- Contribution to journal › Article
- 2004
-
Mark
Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients.
(
- Contribution to journal › Article
-
Mark
Assessment of microvessel density in core needle biopsy specimen in breast cancer
(
- Contribution to journal › Article
-
Mark
Tamoxifen response in primary breast cancer with special reference to tumour-specific VEGF-A and VEGFR2
2004)(
- Thesis › Doctoral thesis (compilation)